Law360, New York (April 26, 2016, 10:37 PM EDT) -- Patent suits over abbreviated new drug applications have increased significantly over the last two years, and a handful of major firms have positioned themselves as the go-to counsel for the high-stakes cases, handling more of them than any other firm, according to a report released Tuesday.
The 2015 Hatch-Waxman / ANDA Litigation Report by the data analytics firm Lex Machina found that there were 467 ANDA suits filed over planned generic drugs in 2015, up from 435 in 2014, and considerably above the average of 269 filed each year between 2009 and 2013.
Click to view interactive version
Since 2009, companies...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!